GlassScriptPhysician profile
Joseph Dicomo
NPI 1356755417
$4,783.82
in general payments reported to CMS, 2019-2025
48 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.91 · 2020: $115 · 2021: $920 · 2022: $822 · 2023: $717 · 2024: $1,213 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endomagnetics LTD | $565.30 | 2020-2024 | Magtrace, Magseed |
| Hologic INC | $307.91 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $281.55 | 2021-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $269.90 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $262.89 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Medtronic, INC. | $239.96 | 2022-2023 | Medtronic Reusable Instruments |
| Blueprint Medicines Corporation | $185.32 | 2021-2025 | Ayvakit |
| Stemline Therapeutics INC. | $169.21 | 2025 | Orserdu |
| Janssen Biotech, INC. | $168.49 | 2021-2025 | Darzalex, Carvykti, Tecvayli |
| Stryker Corporation | $167.27 | 2022-2024 | Molli, Spy-Phi System |
| Celgene Corporation | $145.44 | 2021-2023 | Opdualag |
| Davol INC. | $136.63 | 2025 | Arista |
| Genzyme Corporation | $130.53 | 2021-2024 | |
| Madrigal Pharmaceuticals | $125.51 | 2025 | Rezdiffra |
| Axogen | $116.78 | 2024 | Axoguard Nerve Protector, Axoguard Ha+ Nerve Protector, Axoguard Nerve Cap |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $91.80 | 2021-2024 | Enhertu |
| Lilly USA, LLC | $90.87 | 2022-2024 | Verzenio |
| Pfizer INC. | $83.22 | 2023-2024 | |
| Incyte Corporation | $80.86 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Amgen INC. | $74.93 | 2021-2023 | Lumakras |
| Myriad Genetic Laboratories, INC. | $68.94 | 2021 | |
| Genmab U.S., INC. | $68.75 | 2024-2025 | Tivdak |
| Foundation Medicine, INC. | $65.91 | 2019 | |
| Morphosys, US INC. | $62.53 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $60.20 | 2020-2024 | Xpovio |
| Exelixis INC. | $58.77 | 2023-2024 | Cabometyx |
| Genentech USA, INC. | $58.14 | 2023-2024 | Columvi, Alecensa, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $52.70 | 2020-2023 | |
| Seagen INC. | $50.28 | 2021-2022 | |
| Sobi, INC | $47.76 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $43.83 | 2021-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $42.00 | 2021-2022 | |
| Kyowa Kirin, INC. | $39.27 | 2020-2024 | Poteligeo |
| Eisai INC. | $37.47 | 2021-2024 | |
| Molli Surgical (US) INC | $33.96 | 2023 | |
| Elucent Medical | $29.60 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $28.78 | 2024 | Libtayo |
| Tersera Therapeutics LLC | $28.00 | 2021 | |
| Iovance Biotherapeutics, INC. | $27.95 | 2025 | Amtagvi |
| Springworks Therapeutics, INC. | $25.38 | 2024 | Ogsiveo |
| Adaptive Biotechnologies Corporation | $25.12 | 2025 | Clonoseq |
| Takeda Pharmaceuticals U.S.A., INC. | $24.83 | 2024 | Fruzaqla |
| Deciphera Pharmaceuticals INC. | $22.86 | 2023 | Qinlock |
| Boston Scientific Corporation | $21.60 | 2024 | |
| Puma Biotechnology, INC. | $18.25 | 2024 | |
| Aveo Pharmaceuticals, INC. | $16.62 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.59 | 2023 | Onivyde, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $13.36 | 2023 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dicomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.